Prasinezumab

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NamePrasinezumab
Drug Alias NamePRX-002RO-7046015NEOD-002RG-7935
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionSynuclein alpha inhibitors
TargetsSynuclein alpha
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[19
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesProthena
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A